The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT

Journal of Virology
Joeri AuwerxJ Balzarini

Abstract

The phenylmethylthiazolylthiourea (PETT) derivative MSK-076 shows, besides high potency against human immunodeficiency virus type 1 (HIV-1), marked activity against HIV-2 (50% effective concentration, 0.63 microM) in cell culture. Time-of-addition experiments pointed to HIV-2 reverse transcriptase (RT) as the target of action of MSK-076. Recombinant HIV-2 RT was inhibited by MSK-076 at 23 microM. As was also found for HIV-1 RT, MSK-076 inhibited HIV-2 RT in a noncompetitive manner with respect to dGTP and poly(rC).oligo(dG) as the substrate and template-primer, respectively. MSK-076 selected for A101P and G112E mutations in HIV-2 RT and for K101E, Y181C, and G190R mutations in HIV-1 RT. The selected mutated strains of HIV-2 were fully resistant to MSK-076, and the mutant HIV-2 RT enzymes into which the A101P and/or G112E mutation was introduced by site-directed mutagenesis showed more than 50-fold resistance to MSK-076. Mapping of the resistance mutations to the HIV-2 RT structure ascertained that A101P is located at a position equivalent to the nonnucleoside RT inhibitor (NNRTI)-binding site of HIV-1 RT. G112E, however, is distal to the putative NNRTI-binding site in HIV-2 RT but close to the active site, implying a novel mole...Continue Reading

References

Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C K ShihJ A Griffin
Dec 1, 1989·Journal of Medicinal Chemistry·T MiyasakaE De Clercq
Dec 29, 1989·Biochemical and Biophysical Research Communications·M BabaT Miyasaka
Apr 1, 1995·Nature Structural Biology·J RenD Stuart
Apr 1, 1995·Nature Structural Biology·R EsnoufD Stuart
Jun 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E J CalderónM Leal
Apr 1, 1996·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·G YangV R Prasad
Aug 31, 2001·Bioorganic & Medicinal Chemistry Letters·D W LudoviciP A Janssen
Oct 19, 2002·Proceedings of the National Academy of Sciences of the United States of America·J RenD K Stammers
Jan 3, 2003·Protein Expression and Purification·Louise E BirdDavid K Stammers

❮ Previous
Next ❯

Citations

Dec 19, 2013·Antiviral Research·Luis Menéndez-Arias, Mar Alvarez
Mar 15, 2016·Journal of Molecular Graphics & Modelling·Sudheer S Kurup, Kaustubh A Joshi
Mar 29, 2008·Virus Research·Nicolas Sluis-Cremer, Gilda Tachedjian
Apr 18, 2006·Antiviral Research·Sonia de CastroSonsoles Velázquez
Dec 8, 2004·Current Opinion in Structural Biology·Stefan G SarafianosEddy Arnold

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.